|
Painreform Ltd (NASDAQ: PRFX) |
|
|
|
Painreform Ltd's Quick Ratio
PRFX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2024, Quick Ratio deteriorated to 1.61 a new company low.
Within Major Pharmaceutical Preparations industry 313 other companies have achieved higher Quick Ratio than Painreform Ltd in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 0 to 1283.
Explain Quick Ratio?
How much Cash & cash equivalents PRFX´s has?
What are PRFX´s Current Liabilities?
Select the Comparisons :
|
|
Select the Ratio:
|
|
PRFX Quick Ratio |
(Dec 31 2024) Q4 |
0 Q3 |
0 Q2 |
0 Q1 |
(Dec 31 2022) Q4 |
Y / Y Current Liabilities Change |
103.21 % |
103.21 % |
103.21 % |
103.21 % |
31.89 % |
Y / Y Cash & cash equivalent Change |
-58.09 % |
-58.09 % |
-58.09 % |
-58.09 % |
-38.5 % |
Quick Ratio MRQ |
1.61 |
1.61 |
1.61 |
1.61 |
7.8 |
PRFX's Total
Ranking |
# 1283 |
# 0 |
# 0 |
# 1301 |
# |
Seq. Current Liabilities Change |
0 % |
0 % |
0 % |
103.21 % |
0 % |
Seq. Cash & cash equivalent Change |
0 % |
0 % |
0 % |
-58.09 % |
0 % |
Quick Ratio fourth quarter 2024 Company Ranking |
Within: |
No. |
Major Pharmaceutical Preparations Industry |
# 314 |
Healthcare Sector |
# 558 |
Overall Market |
# 1283 |
Quick Ratio Statistics |
High |
Average |
Low |
16.72 |
8.71 |
1.61 |
(Dec 31 2021) |
|
(Dec 31 2024) |
Cumulative Painreform Ltd's Quick Ratio
PRFX's Quick Ratio for the trailling 12 Months
PRFX Quick Ratio |
(Dec 31 2024) 12 Months |
0 12 Months |
0 12 Months |
0 12 Months |
(Dec 31 2022) 12 Months |
Y / Y Current Liabilities TTM Growth |
103.21 % |
88.82 % |
72.45 % |
53.67 % |
31.89 % |
Y / Y Cash & cash equivalent TTM Growth |
-58.09 % |
-51.2 % |
-45.96 % |
-41.83 % |
-38.5 % |
Quick Ratio TTM |
1.61 |
2.48 |
3.65 |
5.3 |
7.8 |
Total Ranking TTM |
# 3502
| # 0
| # 0
| # 2770
| #
|
Seq. Current Liabilities TTM Growth |
14.54 % |
17.02 % |
20.51 % |
25.8 % |
6.43 % |
Seq. Cash & cash equivalent TTM Growth |
-25.73 % |
-20.47 % |
-16.99 % |
-14.52 % |
-13.53 % |
News about Painreform Ltd Quick Ratio |
PainReform s Public Offering Signals Growth in Clinical-Stage Pharmaceutical Industry In a recent announcement, PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, unveiled the pricing of its public offering, marking a significant milestone for the company s growth. The offering includes 5,000,000 of PainReform s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 5,000,000 ordinary shares, with a combined public offering price of $0.80 per share (or per ordinary share equivalent) and accompanying warrant. The decision to go public with this offering is a strategic move by PainReform to secure necessary funding for their ongoing initiatives in the reformulation of established therapeutics. The proceeds from the offering will support the company s clinical trials and the development of novel treatments, aiming to address unmet medical needs in various therapeutic areas.
|
PainReform Ltd Announces Exercise of Warrants, Garnering Approximately $1.3 Million in Gross Proceeds TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) PainReform Ltd (Nasdaq: PRFX), a leading clinical-stage specialty pharmaceutical company specializing in the reformulation of established therapeutics, has recently made a significant announcement. The company revealed the immediate exercise of certain outstanding warrants, enabling the purchase of up to 467,896 ordinary shares. These warrants were initially issued by PainReform in July 2023 and will now be exercised at a reduced price of $2.85 per ordinary share, as opposed to the original exercise price of $9.00 per share. The ordinary shares acquired through the exercise of warrants are registered under an effective registration statement on Form F-1 (File No. 333-274220). The completion of this offering is expected to take place around December 29, 2023, subject to the fulfillment of customary closing conditions.
|
On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2024 to $2.66 millions, cumulative Quick Ratio decreased to 1.61 below the average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 446 other companies have achieved higher Quick Ratio than Painreform Ltd. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from 0 to 3502.
Explain Quick Ratio?
How much Cash & cash equivalents PRFX´s has?
What are PRFX´s Current Liabilities?
TTM Quick Ratio Company Ranking |
Within: |
No. |
Within the Major Pharmaceutical Preparations Industry |
# 447 |
Healthcare Sector |
# 914 |
Within the Market |
# 3502 |
trailing twelve months Quick Ratio Statistics |
High |
Average |
Low |
16.72 |
10.43 |
1.61 |
(Dec 31 2021) |
|
(Dec 31 2024) |
|